IGM Biosciences Inc logo

IGMS - IGM Biosciences Inc Share Price

$52.8 6.3  13.6%

Last Trade - 8:54pm

Sector
Healthcare
Size
Mid Cap
Market Cap £1.38bn
Enterprise Value £1.19bn
Revenue £n/a
Position in Universe 1649th / 6323
Bullish
Bearish
Unlock IGMS Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

IGMS Revenue Unlock IGMS Revenue

Net Income

IGMS Net Income Unlock IGMS Revenue

Normalised EPS

IGMS Normalised EPS Unlock IGMS Revenue

PE Ratio Range

IGMS PE Ratio Range Unlock IGMS Revenue

Dividend Yield Range

IGMS Dividend Yield Range Unlock IGMS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
IGMS EPS Forecasts Unlock IGMS Revenue
Profile Summary

IGM Biosciences Inc is a biotechnology company engaged in the development of engineered IgM antibodies for the treatment of cancer patients. It has developed IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. The Company’s lead product candidates are IGM-2323: CD20 x CD3 and Death Receptor 5 (DR5). Its IgM platform enables to create a broad pipeline of product candidates. The Company is also conducting research and discovery programs on CD3 T cell engaging antibodies; T cell stimulating antibodies, including antibodies that target T cell stimulatory members of the TNFrSF; and antibodies that are intended to deliver IL-15 to a target to enhance cancer immune responses while limiting systemic toxicity. Its product pipelines also include CD20 x CD3, CD123 x CD3, CD38 x CD3, solid tumor target x CD3 programs, OX40 and glucocorticoid-induced TNFr-related protein (GITR).

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated October 13, 2012
Public Since September 18, 2019
No. of Shareholders: 33
No. of Employees: 64
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 36,967,104
Free Float (0.0%)
Eligible for
ISAs
SIPPs
IGMS Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for IGMS
Upcoming Events for IGMS
Similar to IGMS
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.